{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T20:59:42Z","timestamp":1770325182828,"version":"3.49.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1124\/dmd.120.090878","type":"journal-article","created":{"date-parts":[[2020,6,2]],"date-time":"2020-06-02T05:25:11Z","timestamp":1591075511000},"page":"655-661","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["NADPH-Independent Inactivation of CYP2B6 and NADPH-Dependent Inactivation of CYP3A4\/5 by PBD: Potential Implication for Assessing Covalent Modulators for Time-Dependent Inhibition"],"prefix":"10.1016","volume":"48","author":[{"given":"Mika","family":"Kosaka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donglu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhengyin","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.120.090878_bib1","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.cbi.2014.12.009","article-title":"Mechanism-based inactivation of cytochrome P450 2B6 by isoimperatorin","volume":"226","author":"Cao","year":"2015","journal-title":"Chem Biol Interact"},{"key":"10.1124\/dmd.120.090878_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/187152009787047743","article-title":"Pyrrolo[2,1-c][1,4]benzodiazepine as a scaffold for the design and synthesis of anti-tumour drugs","volume":"9","author":"Cipolla","year":"2009","journal-title":"Anticancer Agents Med Chem"},{"key":"10.1124\/dmd.120.090878_bib28","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1021\/jm030897l","article-title":"Linker length modulates DNA crosslinking reactivity and cytotoxic potency of C8\/C8\u2032 ether-linked C2-exo-unsaturated pyrrolo[2,1-c][1,4]benzodiazepine (PBD) dimers","volume":"47","author":"Gregson","year":"2004","journal-title":"J Med Chem"},{"key":"10.1124\/dmd.120.090878_bib3","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1517\/13543784.2011.573477","article-title":"The development of pyrrolobenzodiazepines as antitumour agents","volume":"20","author":"Hartley","year":"2011","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1124\/dmd.120.090878_bib4","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1021\/tx7002504","article-title":"Mechanism-based inactivation of human cytochromes p450s: experimental characterization, reactive intermediates, and clinical implications","volume":"21","author":"Hollenberg","year":"2008","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/dmd.120.090878_bib27","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1158\/1535-7163.MCT-07-0475","article-title":"Inhibition of DNA binding of the NF-Y transcription factor by the pyrrolobenzodiazepine-polyamide conjugate GWL-78","volume":"7","author":"Kotecha","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"10.1124\/dmd.120.090878_bib6","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1021\/acs.chemrestox.5b00373","article-title":"What are the potential sites of protein arylation by N-Acetyl-p-benzoquinone imine (NAPQI)?","volume":"28","author":"Leeming","year":"2015","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/dmd.120.090878_bib7","doi-asserted-by":"crossref","first-page":"335","DOI":"10.3109\/00498254.2015.1077403","article-title":"Mechanism-based inactivation of cytochrome P450 2B6 by isopsoralen","volume":"46","author":"Lu","year":"2016","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.120.090878_bib8","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1002\/anie.201510610","article-title":"From anthramycin to pyrrolobenzodiazepine (PBD)-containing antibody\u2013drug conjugates (ADCs)","volume":"56","author":"Mantaj","year":"2017","journal-title":"Angew Chem Int Ed Engl"},{"issue":"11","key":"10.1124\/dmd.120.090878_bib9","doi-asserted-by":"crossref","first-page":"4135","DOI":"10.1021\/bi0479813","article-title":"Sequence-selective interaction of the minor-groove interstrand cross-linking agent SJG-136 with naked and cellular DNA: footprinting and enzyme inhibition studies","volume":"44","author":"Martin","year":"2005","journal-title":"Biochemistry"},{"key":"10.1124\/dmd.120.090878_bib10","doi-asserted-by":"crossref","first-page":"730","DOI":"10.2174\/138920009789895534","article-title":"Substrate specificity, regulation, and polymorphism of human cytochrome P450 2B6","volume":"10","author":"Mo","year":"2009","journal-title":"Curr Drug Metab"},{"issue":"39","key":"10.1124\/dmd.120.090878_bib24","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1124\/dmd.111.038596","article-title":"An evaluation of the dilution method for identifying metabolism-dependent inhibitors of cytochrome P450 enzymes","volume":"Drug Metab Dispos 39:1370-1387","author":"Parkinson","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.120.090878_bib11","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s10637-018-0655-0","article-title":"A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma","volume":"37","author":"Phillips","year":"2019","journal-title":"Invest New Drugs"},{"key":"10.1124\/dmd.120.090878_bib12","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1021\/bi952490r","article-title":"Inhibition of bacteriophage T7 RNA polymerase in vitro transcription by DNA-binding pyrrolo[2,1-c][1,4]benzodiazepines","volume":"36","author":"Puvvada","year":"1997","journal-title":"Biochemistry"},{"issue":"16","key":"10.1124\/dmd.120.090878_bib13","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1093\/nar\/21.16.3671","article-title":"A quantitative assay to measure the relative DNA-binding affinity of pyrrolo[2,1-c] [1,4]benzodiazepine (PBD) antitumour antibiotics based on the inhibition of restriction endonuclease BamHI","volume":"21","author":"Puvvada","year":"1993","journal-title":"Nucleic Acids Res"},{"key":"10.1124\/dmd.120.090878_bib25","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s00280-010-1517-4","article-title":"Pharmacokinetics, pharmacodynamics and metabolism of the dimeric pyrrolobenzodiazepine SJG-136 in rats","volume":"68","author":"Reid","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1124\/dmd.120.090878_bib14","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1124\/jpet.103.056127","article-title":"Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine","volume":"308","author":"Richter","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.120.090878_bib15","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1517\/17425255.3.1.51","article-title":"Time-dependent CYP inhibition","volume":"3","author":"Riley","year":"2007","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1124\/dmd.120.090878_bib26","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.cbi.2015.05.024","article-title":"Synthetic modified pyrrolo[1,4] benzodiazepine molecules demonstrate selective anticancer activity by targeting the human ligase 1 enzyme: an in silico and in vitro mechanistic study","volume":"237","author":"Shameem","year":"2015","journal-title":"Chem-Biol Interact"},{"key":"10.1124\/dmd.120.090878_bib16","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1124\/dmd.112.046979","article-title":"Inhibition of bupropion metabolism by selegiline: mechanism-based inactivation of human CYP2B6 and characterization of glutathione and peptide adducts","volume":"40","author":"Sridar","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.120.090878_bib17","doi-asserted-by":"crossref","first-page":"598","DOI":"10.2174\/138920008785821710","article-title":"CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme","volume":"9","author":"Wang","year":"2008","journal-title":"Curr Drug Metab"},{"key":"10.1124\/dmd.120.090878_bib18","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1124\/dmd.110.032292","article-title":"Characterization of HKI-272 covalent binding to human serum albumin","volume":"38","author":"Wang","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.120.090878_bib19","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1182\/blood-2017-10-813493","article-title":"ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies","volume":"131","author":"Zammarchi","year":"2018","journal-title":"Blood"},{"key":"10.1124\/dmd.120.090878_bib29","doi-asserted-by":"crossref","first-page":"743","DOI":"10.2217\/14622416.8.7.743","article-title":"Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance","volume":"8","author":"Zanger","year":"2007","journal-title":"Pharmacogenetics"},{"key":"10.1124\/dmd.120.090878_bib20","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1124\/dmd.119.087023","article-title":"Exposure-efficacy analysis of antibody-drug conjugates delivering an excessive level of payload to tissues","volume":"47","author":"Zhang","year":"2019","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.120.090878_bib21","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1124\/dmd.104.001412","article-title":"Metabolism, pharmacokinetics, and protein covalent binding of radiolabeled Maxipost (BMS-204352) in humans","volume":"33","author":"Zhang","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.120.090878_bib22","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1021\/acsmedchemlett.6b00233","article-title":"Linker immolation determines cell killing activity of disulfide-linked pyrrolobenzodiazepine antibody-drug conjugates","volume":"7","author":"Zhang","year":"2016","journal-title":"ACS Med Chem Lett"},{"issue":"4","key":"10.1124\/dmd.120.090878_bib23","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1158\/1078-0432.CCR-18-0333","article-title":"An anti-CLL-1 antibody-drug conjugate for the treatment of acute myeloid leukemia","volume":"25","author":"Zheng","year":"2019","journal-title":"Clin Cancer Res"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624079005?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624079005?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.120.090878","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T18:57:32Z","timestamp":1739905052000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624079005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S0090955624079005"],"URL":"https:\/\/doi.org\/10.1124\/dmd.120.090878","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"NADPH-Independent Inactivation of CYP2B6 and NADPH-Dependent Inactivation of CYP3A4\/5 by PBD: Potential Implication for Assessing Covalent Modulators for Time-Dependent Inhibition","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.120.090878","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}